Formosa Laboratories, Inc. (TPE:4746)

Taiwan · Delayed Price · Currency is TWD

52.30

+0.10 (0.19%)

Jun 18, 2026, 1:30 PM CST

-22.75% (1Y)

Market Cap	6.29B -25.1%
Revenue (ttm)	4.77B +0.7%
Net Income	339.32M -9.2%
EPS	2.79 -9.7%
Shares Out	120.26M
PE Ratio	18.74
Forward PE	n/a
Dividend	3.00 (5.74%)
Ex-Dividend Date	Aug 21, 2025

Volume	705,650
Open	52.80
Previous Close	52.20
Day's Range	51.80 - 53.30
52-Week Range	50.00 - 72.00
Beta	0.53
Analysts	Buy
Price Target	88.00 (+68.26%)
Earnings Date	Aug 13, 2026

About Formosa Laboratories

Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, a... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1985

Employees 280

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4746

Full Company Profile

Financial Performance

In 2025, Formosa Laboratories's revenue was 4.85 billion, an increase of 2.54% compared to the previous year's 4.73 billion. Earnings were 441.11 million, an increase of 180.48%.

Financial Statements